Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or...
CooperSurgical, a global leader in fertility and women's health, and Fulgent Genetics, Inc. , a technology-based company with a well-established clinical diagnostic business and...
Iambic Therapeutics, a biotechnology company developing novel therapeutics using its AI-driven discovery platform, announced the appointment of oncologist and industry veteran Neil Josephson, M.D.,...
Domain Therapeutics, a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors announces the appointment of Sean A. MacDonald...
Here is Read Magazine’s Weekly Roundup of the top news from global markets. In this fast-paced world, breaking down information helps readers grasp the...
